Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06632561
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-10-06
Brief Title:
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HFrEF
Brief Summary:
The study is a short to mid-term randomized single-blind placebo controlled study that aimed to detect the effects of empagliflozin a sodium-glucose cotransporter-2 inhibitor compared to placebo on LV end-diastolic and end-systolic volumes LV ejection fraction N-terminal pro-B-type natriuretic peptide NT-proBNP functional capacity and quality of life QoL among non-diabetic patients with HFrEF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None